Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia.

Importance Aortic valve stenosis (AS) is the most common valve disease. Elevated levels of low-density lipoprotein (LDL) cholesterol are a risk factor; however, lipid-lowering treatment seems not to prevent progression of AS. The importance of LDL cholesterol in the development of AS thus remains unclear. People with familial hypercholesterolemia (FH) have elevated LDL cholesterol levels from birth and until lipid-lowering treatment starts. Thus, FH may serve as a model disease to study the importance of LDL cholesterol for the development of AS. Objective To compare the incidence of AS per year in all genetically proven patients with FH in Norway with the incidence of these diseases in the total Norwegian population of about 5 million people. Design, Setting, and Participants This is a registry-based prospective cohort study of all Norwegian patients with FH with regard to first-time AS between 2001 and 2009. All genotyped patients with FH in Norway were compared with the total Norwegian populations through linkage with the Cardiovascular Disease in Norway project and the Norwegian Cause of Death Registry regarding occurrence of first-time AS. Data were analyzed between January 1, 2018, and December 31, 2018. Main Outcomes and Measures Standardized incidence ratios. Results In total, 53 cases of AS occurred among 3161 persons (1473 men [46.6%]) with FH during 18 300 person-years of follow-up. Mean age at inclusion and at time of AS were 39.9 years (range, 8-91 years) and 65 years (range, 44-88 years), respectively. Total standardized incidence ratios were 7.9 (95% CI, 6.1-10.4) for men and women combined, 8.5 (95% CI, 5.8-12.4) in women, and 7.4 (95% CI, 5.0-10.9) in men, respectively, indicating marked increased risk of AS compared with the general Norwegian population. Conclusions and Relevance In this prospective registry study, we demonstrate a marked increase in risk of AS in persons with FH.

[1]  K. Arnesen,et al.  LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. , 2019, Journal of clinical lipidology.

[2]  G. Tell,et al.  Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia , 2018, Heart.

[3]  H. Crijns,et al.  Calcific aortic valve stenosis: hard disease in the heart , 2017, European heart journal.

[4]  G. Tell,et al.  Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. , 2017, Atherosclerosis.

[5]  L. Pérez de Isla,et al.  Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. , 2016, Journal of clinical lipidology.

[6]  R. Nicoll,et al.  The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis. , 2016, Atherosclerosis.

[7]  A. Kurata,et al.  Increased Aortic Valve Calcification in Familial Hypercholesterolemia: Prevalence, Extent, and Associated Risk Factors. , 2015, Journal of the American College of Cardiology.

[8]  Vilmundur Gudnason,et al.  Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.

[9]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[10]  H. Schirmer,et al.  The evolving epidemiology of valvular aortic stenosis. The Tromsø Study , 2012, Heart.

[11]  G. Tell,et al.  Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia: A Register Study From Norway , 2019, Stroke.

[12]  J. Sterne,et al.  Essential Medical Statistics , 2003 .